



DAFTAR PUSTAKA

1. Tosto MG, Momi SK, Asherson P, Malki K. A systematic review of attention deficit hyperactivity disorder (ADHD) and mathematical ability: Current findings and future implications. *BMC Med.* 2015; **13**
2. Sengupta SM.. Differential association between the norepinephrine transporter gene and ADHD: Role of sex and subtype. *J. Psychiatry Neurosci.* 2012; **37**, 129–137
3. Rader R, McCauley L, Callen EC. Current strategies in the diagnosis and treatment of childhood attention-deficit/hyperactivity disorder. *Am. Fam. Physician.* 2009; **79**, 657–65
4. Noordermeer SD. Risk factors for comorbid oppositional defiant disorder in attention-deficit/hyperactivity disorder. *Eur. Child Adolesc. Psychiatry* 2017; **26**, 1155–1164
5. American Psychiatric Association. Attention Deficit / Hyperactivity Disorder. (2013).
6. Feldman HM, Reiff MI. Attention Deficit-Hyperactivity Disorder in Children and Adolescents. *N. Engl. J. Med.* 2014; **370**, 838–846
7. Hoseini BL, Abbasi MA, Moghaddam HT, Khademi G, Saeidi M. Attention deficit hyperactivity disorder (ADHD) in children: A short review and literature. *Int. J. Pediatr.* 2014; **2**, 445–452
8. Indriyani S, Soetjiningsih S, Ardjana IE, Windiani IT. Prevalensi dan Faktor-Faktor Risiko Gangguan Pemusatkan Perhatian Anak dan Hiperaktivitas di Klinik Tumbuh Kembang RSUP Sanglah Denpasar. *Sari Pediatr.* 2016; **9**, 335
9. Pramudita. Evaluasi penggunaan obat pada terapi anak attention deficit hyperactivity disorder di RSUP dr. sardjito yogyakarta. 2017 1–25
10. Adiputra IMS, Sutarga M, Indraguna Pinatih GN. Faktor Risiko Attention Deficit Hyperactivity Disorder (ADHD) pada Anak di Denpasar. *Public Heal. Prev. Med. Arch.* 2015; **3**, 43–48
11. Faraone S, Asherson P, Banaschewski T, Biederman JB. Attention-deficit hyperactivity disorder (ADHD). *J. Child Neurol.* 2015; **1**, 798–814
12. Larsson H, Sariaslan A, Langström N, D’Onofrio B, Lichtenstein P. Family income in early childhood and subsequent attention deficit/hyperactivity disorder: A quasi-experimental study. *J. Child Psychol. Psychiatry Allied Discip.* 2014; **55**, 428–435
13. Curatolo P, D’Agati E. The neurobiological basis of ADHD. *Ilitalian journal of pediatrics.* 2010; **39**, 185–204 (2015).
14. Faraone S, Mick E. Molecular Genetics of Attention Deficit Hyperactivity Disorder. *Psychiatr Clin North Am.* 2011; **33**, 1–20 (2011).
15. Grizenko N, Fortier ME, Joober R. Maternal Stress During Pregnancy, ADHD Symptomatology in Children and Genotype: Gene-Environment Interaction. *J. Can. Acad. Child Adolesc. Psychiatry* 2018; **21**, 9–15
16. Strang-Karlsson S. Very low birth weight and behavioral symptoms of attention deficit hyperactivity disorder in young adulthood: the Helsinki



- study of very-low-birth-weight adults. *Am. J. Psychiatry* 2008. **165**, 1345–1353
17. Kollins SH, Adcock RA. ADHD, altered dopamine neurotransmission, and disrupted reinforcement processes: Implications for smoking and nicotine dependence. *Prog. Neuro-Psychopharmacology Biol. Psychiatry* 2014. **52**, 70–78
 18. Stahl SM. *Chapter 12: Attention deficit and hyperactivity disorder in Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th edition)* 2013.
 19. Graham J. European guidelines on managing adverse effects of medication for ADHD. *Eur. Child Adolesc. Psychiatry* 2011. **20**, 17–37 (2011).
 20. Montoya A. Prognostic factors of improvement in health-related quality of life in atomoxetine-treated children and adolescents with attention-deficit/hyperactivity disorder, based on a pooled analysis. *ADHD Atten. Deficit Hyperact. Disord.* 2014. **6**, 25–34
 21. Holton KF, Nigg JT. The Association of Lifestyle Factors and ADHD in Children. *J. Atten. Disord.* 2016. doi:10.1177/1087054716646452
 22. Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: A review and suggested future directions. *Biol. Psychiatry* 2005. **57**, 1273–1284
 23. Gale C, Sciberras C, Galea M. Attention deficit hyperactivity disorder (adhd): An overview. 2013. **03**, 16–21
 24. Owens J, Jackson H. Attention-deficit/hyperactivity disorder severity, diagnosis, & later academic achievement in a national sample Jayanti. *Soc Sci Res* 2016. **25**, 289–313 (2016).
 25. Reynolds CR, Kamphaus RW. Attention-Deficit / Hyperactivity Disorder (ADHD). *DSM-5™ Diagnostic Criteria*. 2013
 26. Hurtig T. ADHD symptoms and subtypes: Relationship between childhood and adolescent symptoms. *J. Am. Acad. Child Adolesc. Psychiatry* 2007. **46**, 1605–1613
 27. Arnett A, Pennington BF, Willcutt EG, Defries JC, Olson RK. Sex differences in ADHD symptom severity. *J. Child Psychol. Psychiatry Allied Discip.* 2015. **56**, 632–639
 28. Storebø OJ. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. *BMJ* 2015. **351**,
 29. Briars L, Todd T. A review of pharmacological management of attention-deficit/hyperactivity disorder. *J. Pediatr. Pharmacol. Ther.* 2016. **21**, 192–206.
 30. Winterstein AG. Cardiac Safety of Central Nervous System Stimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. *Pediatrics* 2007. **120**, e1494–e1501
 31. Liang EF.. The effect of methylphenidate and atomoxetine on heart rate and systolic blood pressure in young people and adults with attention-deficit hyperactivity disorder (ADHD): Systematic review, meta-analysis, and meta-regression. *Int. J. Environ. Res. Public Health* 2018. **15**, (2018).



- disturbances and ADHD. *Genes (Basel)*. 2019. **10**,
49. Natalita C, Sekartini R, Poesponegoro H. Skala Gangguan Tidur untuk Anak (SDSC) sebagai Instrumen Skrining Gangguan Tidur pada Anak Sekolah Lanjutan Tingkat Pertama. *Sari Pediatr*. 2016. **12**, 365
50. Setoodeh A, Teleffson S. Attention Deficit Hyperactivity Disorder and Self-control. *Sch. Psychol. Int.* 2007. **13**, 339–345
51. Dogra DP. ADHD: Pathophysiology, Management, and Assessment Scales. *J. Med. Sci. Clin. Res.* 2018. **6**, 341–347
52. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: Impact of remission definition and symptom type. *Am. J. Psychiatry* 2000. **157**, 816–818
53. Wiguna T. Dampak Metilfenidat Kerja Panjang 20 Mg Terhadap Pola Perbaikan Gejala Klinis pada Anak dengan Gangguan Pemusatan Perhatian/Hiperaktivitas (GPPH). *Sari Pediatr*. 2009. **11**, 142–149
54. Kaunang TMD, Dundu AE. Komorbiditas pada anak gangguan pemusatan perhatian dan hiperaktivitas (GPPH) pada 20 Sekolah Dasar di Kota Manado. 2016. **4**
55. Charach A. Children with Attention Deficit Hyperactivity Disorder : Epidemiology , Comorbidity and Assessment. 2010. 1–8
56. Westerlund J, Holmberg K, Näswall K, Fernell,E. The Conners' 10-item scale: Findings in a total population of Swedish 10-11-year-old children. *Acta Paediatr. Int. J. Paediatr.* 2009. **98**, 828–833
57. Ghanizadeh, A. Agreement between diagnostic and statistical manual of mental disorders, Fourth Edition, and the proposed DSM-V attention deficit hyperactivity disorder diagnostic criteria: An exploratory study. *Compr. Psychiatry* 2013. **54**, 7–10
58. Wang Y, Huang L. Maternal Smoking and Attention- Deficit / Hyperactivity Disorder in Offspring : A Meta-analysis. 2018. **141**,
59. Castejón OJ. Maternal Stress, Pregnancy Diseases and Child Hyperactivity and Attention Deficit (ADHD). *Biomed. J. Sci. Tech. Res.* 2018. **12**, 9118–9126
60. Cormier E. Attention deficit/hyperactivity disorder: a review and update. *J. Pediatr. Nurs.* 2008. **23**, 345–57



UNIVERSITAS
GADJAH MADA

KUALITAS HIDUP PADA PASIEN DENGAN GANGGUAN PEMUSATAN PERHATIAN DAN
HIPERAKTIVITAS DAN GANGGUAN
PERILAKU MENENTANG

IA ARIWINTAN A, dr. Retno Sutomo, Ph.D, Sp. A(K); dr. Amalia Setyati, Sp. A(K)

Universitas Gadjah Mada, 2019 | Diunduh dari <http://etd.repository.ugm.ac.id/>

PERSETUJUAN SETELAH PENJELASAN

(*Informed Consent*)

Saya yang bertanda tangan di bawah ini:

Nama : Jumareno
Umur : 35 thn
Jenis Kelamin : ♂
Pekerjaan : Buruh
Alamat : Gedongan DK I / RT 1, Sagedejo, Sonden, Banjul
Orangtua/wali dari : Aby Rikza P.

Telah menerima dan mengerti penjelasan yang sudah diberikan oleh dokter mengenai pemantauan pengobatan “**Gangguan Pemusatan Perhatian / Hiperaktivitas**”. Dengan kesadaran serta kerelaan sendiri saya mengijinkan anak saya menjadi pasien dalam pemantauan ini.

Saya mengerti sepenuhnya bahwa partisipasi ini bersifat sukarela dan saya dapat menolak mengikuti pemantauan ini. Demikianlah persetujuan ini saya buat tanpa paksaan siapapun.

Yogyakarta, Juli 2017

Pemeriksa

(*Wint M*
Ma Ayu Ananta A.)

Orangtua/Wali

(*J. M*
Bpk. Ju Marno)